Post hoc analysis of two phase 3 SURMOUNT-OSA trials in adults with moderate-to-severe OSA and obesity: tirzepatide vs placebo reduced AHI across subgroups of age, sex, BMI, AHI severity and neck circumference over 52 weeks; descriptive and hypothesis-generating.
Secondary analysis
Falcon et al. Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA